Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5 years of treatment

Hendriksz, Christian J. et al.

University Of Pretoria Repository · Other

elosulfase alfa, long-term extension, morquio a, mucopolysaccharidosis iva, immunogenicity, safety, health sciences articles sdg-03, health sciences articles sdg-04

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 359234
Conceptio Open Knowledge Archive — every document is proof-bundled with source, license, and retrieval metadata.

Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5 years of treatment

Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5 years of treatment